← All trials
NCT05321875
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2022
- Primary completion
- Jun 2, 2026
- Completion date
- Jun 2, 2026
- First posted
- Apr 11, 2022
- Last posted
- Aug 29, 2022
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Autonomous University of MadridLead sponsor
- Universidad Autonoma de MadridStudy chair
- Autonomous University of MadridSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.